logo
  Join        Login             Stock Quote

Integra Lifesciences (IART) Receives FDA Warning Letter For Quality Systems Issues

 November 13, 2012 07:13 AM
 


(By Balaseshan) Integra Lifesciences Holdings Corp. (NASDAQ: IART), a medical device company, said its unit has received a warning letter from the U.S. Food and Drug Administration (FDA) related to quality systems issues at its manufacturing facility located in Andover, England.

Integra NeuroSciences Ltd. received the letter that resulted from an inspection held at the facility in June 2012. The company does not expect to incur material incremental expense during the fourth quarter on remediation activities.

The FDA determined that the company manufactures Intracranial Pressure Monitors and Ultrasonic Aspiration devices, which are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease.

[Related -Futures Retreat On 'Fiscal Cliff', Europe Worries; Microsoft (MSFT) Drops]

This inspection revealed that these devices are adulterated that are not in conformity with the current good manufacturing practice requirements of the Quality System regulation.

The warning letter does not restrict the company's ability to manufacture or ship products or import them into the United States. It also does not require the recall of products.

The company has provided detailed responses to FDA as to its corrective actions on a monthly basis and, since the conclusion of the inspection, has undertaken significant efforts to remediate the observations.

Despite providing detailed responses, the company did not provide completion dates or documentation to show that it had implemented these corrective actions. FDA said a follow-up inspection will be required to assure that corrections and/or corrective actions are adequate.

[Related -Lousy Day With Late Snapback]

"Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. Your firm should investigate and determine the causes of the violations, and take prompt actions to correct the violations and bring the products into compliance," said Steven Silverman, Director - Office of Compliance, Center for Devices and Radiological Health.

The Andover facility manufactures components of the CUSA ultrasonic aspirator system, and intracranial pressure monitors. Sales of products manufactured in the Andover facility constituted less than 3% of Integra's consolidated revenues in the twelve months ended September 30, 2012.

IART closed Monday's regular session up 0.08% at $37.46. The stock has been trading between $23.09 and $43.12 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article image3 US Updates Show Ongoing Growth

Three economic updates today provide more evidence that moderate growth endures for the US. The numbers du read on...

article imageBuy These Solar Stocks Before They Snapback

Sometimes the market hands you a gift. And it would be foolish not to take it. Thanks to general market read on...

article imageInvestors Are Even More Euphoric And Confident.

As noted on the blog last Thursday, even though the market had been down for three straight weeks, last read on...

article imageThe Butterfly Machine

There’s a phenomenon called the Butterfly Effect. One common quotation is “It has been said that something read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center

Related Articles:

A Very Good Day Technically
More Articles on: Medical



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.